Turkish Journal of Nephrology

Autophagy and Autosomal Dominant Polycystic Kidney Disease


Department of Nephrology, İstanbul University, Faculty of Medicine, İstanbul, Türkiye


Division of Renal Diseases and Hypertension, University of Colorado, Anschutz Medical Campus, Colorado, USA

Turkish J Nephrol 2023; 32: 8-15
DOI: 10.5152/turkjnephrol.2023.22103385
Read: 517 Downloads: 246 Published: 30 December 2022

Autophagy is a protective mechanism that ensures cell survival. The mammalian target of rapamycin is the main regulator of autophagy, and mammalian target of rapamycin activation suppresses autophagy. Mammalian target of rapamycin inhibitors, like sirolimus, activate autophagy. Disorders in autophagy regulation are of central importance in many pathophysiological conditions. In the kidney, autophagy is dysregulated in autosomal dominant polycystic kidney disease, acute kidney injury, podocytopathies, transplant rejection, cold preservation ischemia, kidney aging, glomerular disease, and diabetic nephropathy. There are reasons to suspect that autophagy is dysregulated in autosomal dominant polycystic kidney disease. Pkd1 and 2 genes can control autophagy. There is abnormal autophagy in Pkd1 cells and polycystic kidney disease. Mammalian target of rapamycin inhibitors that activate autophagy slow cyst growth. Evidence emerging in polycystic kidney disease cells and polycystic kidney disease animal models shows that direct autophagy inhib ition /acti vation affects cyst growth. The review will focus on the autophagy process, pathways that regulate autophagy, autophagy and kidney pathophysiology, and autophagy and autosomal dominant polycystic kidney disease.

Cite this article as: Oto ÖA, Edelstein CL. Autophagy and autosomal dominant polycystic kidney disease. Turk J Nephrol. 2023;32(1):8-15.

EISSN 2667-4440